NexGard Spectra® protects against all of these key parasites in a single chew
Activity against key dog parasites§
NexGard Spectra® | Advocate® | Bravecto® | Simparica TrioTM | CredelioTM Plus | |
---|---|---|---|---|---|
Fleas | ✓ | ✓ | ✓ | ✓ | ✓ |
Ticks | ✓ | ✓ | ✓ | ✓ | |
Mites | ✓ | ✓ | ✓ | ✓ | |
Roundworms | ✓ | ✓ | ✓ | ✓ | |
Lungworm | ✓ | ✓ | ✓ | ✓ | |
Ear Mites | ✓ | ✓ |
9/10 dogs prefer NexGard Spectra
Hear why practices are choosing NexGard Spectra®
For more information, read the full vet brochure
Explore the latest...
Owner materials
Handy resources, like posters for your veterinary practice, and materials to support your client communications.
Puppy campaign
Engage with new puppy owner clients, helping to keep their new family member happy and healthy while building a lifelong connection with your practice.
Introducing Parassess®
A FREE online, easy-to-use parasite risk checker that helps owners to help you assess their dog’s individual risk. Enables a timely, risk-based prescribing decision in your busy practice.
- Owner materials
- Puppy campaign
- Parassess risk checker
Choose NexGard Spectra®...
-
for dogs
Learn more -
for owners
Learn more -
for practices
Learn more
* Terms and conditions apply, which are available from the contact details below.
† NexGard Spectra® also covers heartworm, hookworms, whipworm and eyeworm. NexGard Spectra®’s mite indication is for treatment of sarcoptic mange, demodicosis and otodectes cynotis. NexGard Spectra® does not cover tapeworm.
†† Caused by Otodectes cynotis.
‡The safety of the veterinary medicinal product has not been established in breeding males. In breeding males, use only according to the benefit-risk assessment by the responsible veterinarian.
§ The table shows activity against fleas, ticks, roundworms, lungworm and mites (sarcoptic and demodectic mange only). Some of the products listed have claims against other parasites. Refer to the Summary of Product Characteristics for each product for full details of the licensed indications.
‖ Treats only demodicosis but not sarcoptic mange.
¶ 9 out of 10 dogs that demonstrated a preference in the studies preferred NexGard Spectra®.
1. Perier N, Carithers DS, Everett WR, et al. Preference of Dogs between Two Oral Formulations of Endectoparasiticides: NexGard Spectra® (Afoxolaner and Milbemycin Oxime) and Simparica TrioTM (Sarolaner, Moxidectin and Pyrantel). Open Journal of Veterinary Medicine 2020;10:155-163.
2. Perier N, Carithers DS, Everett WR, et al. Preference in Dogs of Two Oral Endectoparasiticide Formulations: NexGard Spectra® (Afoxolaner and MilbemycinOxime) and CredelioTM Plus (Lotilaner and Milbemycin Oxime). Open Journal of Veterinary Medicine 2021;11:289-298.
NexGard Spectra® contains afoxolaner and milbemycin oxime. UK: POM-V. Prescription decisions are for the person issuing the prescription alone. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical). Email: vetenquiries@boehringer-ingelheim.com. NexGard Spectra® is a registered trademark of Boehringer Ingelheim Animal Health France SCS, used under licence. ©2024 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: April 2024. UI-CAN-0028-2024. Use Medicines Responsibly.